Abbott Laboratories (ABT) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Abbott Laboratories stock $75.28, price $114, that is 33.7% below the price, quality 68 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
Our calculation puts a fair price 34% below what the stock costs today.
Quality 68/100
Healthy Growth(revenue 5y +5.1 %/yr in USD)
Low debt
Generates free cash flow
2.2% dividend yield · Sustainable
Wide moat67/100
Broad data
Thin margins · 9.8% net margin (TTM)
Mixed vs. peers(8/15)
Neutral coverage
Insiders bought $173,640 (6M) · sold $46.9M
Profit last quarter 44% below a year ago.
Fair value $75.28 · Overvalued (−33.7%)
Risks from the AI analysis
🚩Preterm formula lawsuits and settlements🚩Debt and integration costs from Exact Sciences acquisition🚩Blood-based cancer screening competition post-acquisition
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $81.47 – $134.98 · fair‑value band $52.65 – $95.05 · the $113.60 price screens above the $75.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Abbott Laboratories in your weekly email
Every Wednesday you see whether Abbott Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Show moreShow less
The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test.
In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices.
The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Stock analysis
Abbott Laboratories (ABT) currently trades at $113.60, while our model-based Fair Value estimate is $75.28, 34% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $80.89 per share, and 0 of the 26 models we run sit above the $113.60 price.
Bear case: the Asset-Based group reads lowest at $8.74, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: $52.65 (bear) to $95.05 (bull), the price of $113.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Abbott Laboratories reported revenue of $44.3B in FY2025 versus $43.1B in FY2021, a compound +0.7%/yr. Reported net income was $6.5B in FY2025, compounding −2.0%/yr from FY2021.
Key figures
Market cap $198B Large · P/E ratio 43.0 · P/S ratio 4.11 · EPS (TTM) $2.64 · Dividend yield 2.2% · Net margin 9.8% · Return on equity 10.6% · Return on assets (EBIT) 10.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 67 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 11% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −34%, ABT screens richer than that median.
Fair Value models
Bear$52.65Fair Value $75.28Bull$95.05
Price $113.60 · Downside -33.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.1019 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director bought shares worth $173,640, on May 7, 2026. Over the same period, 3 people sold shares worth $46.9M.
SaleJohn A. McCoy Jr.VICE PRESIDENT AND CONTROLLER2× since Mar 2, 2026: 612 shares, avg. $115.31$70,572Sep 2, 2026
SaleRobert B FordCHAIRMAN AND CEO, Director398,832 shares at $115.85$46.2MAug 25, 2026
SaleLouis H. MorroneEXECUTIVE VICE PRESIDENT2× since Mar 2, 2026: 6,994 shares, avg. $110.77$774,729Aug 11, 2026
BuyJohn G StrattonDirector2,000 shares at $86.82$173,640May 7, 2026
BuyDaniel J StarksDirector2× since Feb 4, 2026: 20,000 shares, avg. $100.69$2.0MApr 27, 2026
BuyPhilip P BoudreauEVP AND CFO2,200 shares at $91.50$201,300Apr 23, 2026
SaleDaniel Gesua Sive SalvadoriEVP AND GROUP PRESIDENT885 shares at $115.58$102,288Mar 2, 2026
SaleMary K MorelandEXECUTIVE VICE PRESIDENT613 shares at $115.58$70,851Mar 2, 2026
SaleEric ShroffSenior Vice President2× since Nov 25, 2025: 2,295 shares, avg. $124.18$284,986Mar 2, 2026
SaleElizabeth C. CushmanEVP, GC AND SECRETARY263 shares at $115.58$30,398Mar 2, 2026
Plus 1 more entries from the last 12 months.
Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.69/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Start year 2020 (pandemic). Over 10 years: +8.1% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+10.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.2%
Dividend (yield on the price)2.2%
Per share before 2004divided by the spin-off factor 1.0688
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8.2% vs 9.6%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 18%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +8.6% a year for the price and +5.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Moderate scale-based moat in devices and diagnostics supports stable margins and cash conversion, yet standard reimbursement risks remain the central weakness.
Main risk: Ongoing lawsuits alleging that Abbott's preterm infant formula caused necrotizing enterocolitis could lead to further large settlements or judgments, hitting the nutrition segment's margins and cash flow.
Bull case: Abbott could use its global scale and reimbursement expertise to expand Exact Sciences tests internationally and integrate them with its diagnostics portfolio, turning the oncology vertical into a sustained growth driver.
Bear case: If integration costs mount, blood-based rivals capture share through easier testing or better reimbursement, and legal liabilities from the nutrition segment persist, the added complexity could outweigh growth benefits and strain overall cash flow.
Abbott plans to spin off its nutrition business into a standalone public company by the end of 2027. This step should allow sharper focus on medical devices, where recent heart device trials showed strong outcomes. The company also lowered its 2026 comparable sales growth target to about 6 percent. Our models see the shares as overvalued, so will the separation accelerate device-led growth or mainly create transition drag?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 322 stocks
Beats the industry median on 8/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−33.7% · Below median
Profitability
Return on equity (12 months)10.6% · Above median
Return on assets7.5% · Top 25%
Net margin (12 months)9.8% · Above median
Operating margin (12 months)11.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)14.5% · Above median
Dividend yield (12 months)2.2% · Above median
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)43.0× · Priciest 25%
P/B3.80× · Priciest 25%
P/S (12 months)4.11× · Pricier than median
Price / free cash flow (fiscal year)26.8× · Pricier than median
EV/EBITDA16.7× · Pricier than median
PEG1.50× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)73· sector 36
PAST (return on equity)42· sector 16
HEALTH (low debt)91· sector 98
DIVIDEND (yield)44· sector 35
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Abbott Laboratories Fair Value". https://www.fairvalue-calculator.com/stock/ABT
Frequently asked questions
Is Abbott Laboratories (ABT) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $75.28 versus a price of $113.60, about 34% lower (overvalued).
What is the fair value of ABT?
Our model-based fair value for Abbott Laboratories is $75.28 (as of Nov 6, 2026), built from audited fundamentals. The current price: $113.60.
What is the quality score of ABT?
Abbott Laboratories has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Abbott Laboratories (ABT)?
Our model-based price target is the fair value of $75.28 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario $52.65, optimistic scenario $95.05. It is a calculation from audited fundamentals, not an analyst target.
What is the Abbott Laboratories stock forecast for 2026?
Our models put fair value at $75.28, about 34% lower versus a price of $113.60 (overvalued). Cautious scenario $52.65, optimistic scenario $95.05. The calculation is refreshed regularly with new filings.
What is the revenue of Abbott Laboratories (ABT)?
Abbott Laboratories reported trailing-twelve-month revenue of about $48.2B (latest available figure, as of Nov 6, 2026).
Does Abbott Laboratories pay a dividend?
Abbott Laboratories currently shows a dividend yield of 2.22% relative to its recent price (as of Nov 6, 2026).
What growth is priced into Abbott Laboratories (ABT)?
For today's price to be fair in a discounted-cash-flow model, Abbott Laboratories would have to grow free cash flow by +11.2 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.1 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of ABT use?
Our models discount Abbott Laboratories at 8.3 %: a base by market capitalisation (large), damped by beta 0.58, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Abbott Laboratories that is +11.2 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has Abbott Laboratories (ABT) delivered so far?
Over the past 5 years revenue at Abbott Laboratories grew +5.1 % a year. The price currently implies +11.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Abbott Laboratories (ABT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Abbott Laboratories (+11.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Abbott Laboratories (ABT)?
The free-cash-flow yield on the price is 3.73 %: that much free cash flow Abbott Laboratories produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Abbott Laboratories (ABT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Abbott Laboratories it is $75.28 per share (as of Nov 6, 2026), against a price of $113.60. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Abbott Laboratories stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ABT trades above its calculated fair value: price $113.60, fair value $75.28, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ABT?
No. The price is what the market pays today ($113.60); the fair value is what the company's own numbers justify ($75.28). For Abbott Laboratories the two are $38.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is Abbott Laboratories worth?
The market values Abbott Laboratories at about $198B (market capitalisation, as of Nov 6, 2026). Per share that is $113.60; our models calculate a fair value of $75.28 per share.
What do the bullish and bearish scenarios say about ABT?
Our models span a range for Abbott Laboratories: cautious scenario $52.65, base $75.28, optimistic $95.05 per share (as of Nov 6, 2026, price $113.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ABT?
Abbott Laboratories trades at a price-to-earnings ratio of 43.0 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $75.28 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2016, FY2020, FY2023 ex one-offs: 35.6. Other multiples: PEG 1.5, P/B 3.8, P/S 4.1, EV/EBITDA 16.7.
What is the PEG ratio of ABT?
The PEG ratio of Abbott Laboratories is 1.50 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Abbott Laboratories (ABT)?
Balance-sheet figures for Abbott Laboratories (as of Nov 6, 2026): return on equity 10.6%, debt of 0.19 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is ABT from its 52-week high?
Abbott Laboratories trades at $113.60, about 11% below its 52-week high of $127.42 and 39% above the low of $81.47 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $75.28 is for.
Which stocks are comparable to Abbott Laboratories?
From the same area (Healthcare) we also value Medtronic plc, Stryker Corporation, Boston Scientific Corporation, Edwards Lifesciences Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Abbott Laboratories stock attractive at the current price?
The data as of Nov 6, 2026: price $113.60, calculated fair value $75.28 (−34%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ABT calculated?
We run Abbott Laboratories through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $75.28, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Abbott Laboratories itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Abbott Laboratories (ABT)?
The closing price on Nov 5, 2026 was $113.60. Our model-based fair value is $75.28, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Abbott Laboratories right now?
The price sits above even our optimistic bull case ($95.05). The favourable scenario is already priced in. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($52.65 to $95.05) leaves room in how you read the outcome.
Key figures of Abbott Laboratories
How large is the market capitalisation of Abbott Laboratories (ABT)?
The market capitalisation of Abbott Laboratories is $198B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Abbott Laboratories (ABT)?
The price-to-sales ratio of Abbott Laboratories is 4.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Abbott Laboratories (ABT)?
Earnings per share at Abbott Laboratories are $2.64 (price ÷ EPS = P/E 43.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Abbott Laboratories (ABT)?
The dividend yield of Abbott Laboratories is 2.2% (payout 95.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Abbott Laboratories (ABT)?
The net margin of Abbott Laboratories is 9.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Abbott Laboratories (ABT)?
The return on equity (ROE) of Abbott Laboratories is 10.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Abbott Laboratories (ABT)?
On an EBIT basis the return on assets of Abbott Laboratories is 10.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Abbott Laboratories (ABT)?
The operating margin of Abbott Laboratories is 11.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Abbott Laboratories (ABT)?
Revenue at Abbott Laboratories is growing +14.5% versus a year earlier (3y avg +0.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Abbott Laboratories (ABT)?
Earnings per share at Abbott Laboratories are growing −43.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Abbott Laboratories (ABT) carry?
The net debt of Abbott Laboratories is $6.5B (fiscal year 2025, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Abbott Laboratories in the live analysis
One click puts Abbott Laboratories on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026